Medicines used in respiratory diseases only seen in children

European Respiratory Journal

Volumn 34, Issue 3, 2009, Pages 531-551

  Lenney, W ^a   Boner, A L ^f   Bont, L ^h   Bush, A ^b   Carlsen, K H ^j   Eber, E ^k   Fauroux, B ^m   Gotz M ^l   Greenough, A ^c   Grigg, J ^d   Hull, J ^e   Kimpen, J ⁱ   Sanchez Luna M ⁿ   De Benedictis, F M ^g  

^a KEELE UNIVERSITY   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF VERONA   (Italy)

^g Salesi Children's Hospital   (Italy)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j OSLO UNIVERSITY HOSPITAL   (Norway)

^k MEDICAL UNIVERSITY OF GRAZ   (Austria)

^l WILHELMINEN HOSPITAL   (Austria)

^m SORBONNE UNIVERSITÉ   (France)

ⁿ Hospital Universitario Materno Infantil   (Spain)

more..

Author keywords

Bronchiolitis; Bronchiolitis obliterans; Bronchopulmonary dysplasia; Croup; Interstitial lung disease; Viral induced wheeze

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ALPHA TOCOPHEROL; ANTIOXIDANT; ANTIVIRUS AGENT; AZITHROMYCIN; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; COPPER ZINC SUPEROXIDE DISMUTASE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DEXAMETHASONE; DIURETIC AGENT; ERYTHROMYCIN; ESTRADIOL; ETHYL NITRATE; HYDROCORTISONE; INOSITOL; IPRATROPIUM BROMIDE; LUNG SURFACTANT; MELATONIN; MONOCLONAL ANTIBODY; MONTELUKAST; NITRIC OXIDE; PENTOXIFYLLINE; PROGESTERONE; RETINOL; SALBUTAMOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC PNEUMONITIS; BONE DEMINERALIZATION; BRAIN HEMORRHAGE; BRONCHIOLITIS; BRONCHIOLITIS OBLITERANS; CEREBRAL PALSY; CHILDHOOD DISEASE; CLINICAL TRIAL; CONGENITAL LUNG DISEASE; CORTICOSTEROID THERAPY; CROUP; DIABETES MELLITUS; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; GLUCOSURIA; HUMAN; HYPERCALCIURIA; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFECTION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; INTRACRANIAL PRESSURE; KIDNEY CALCIFICATION; LOEFFLER PNEUMONIA; LOW DRUG DOSE; LUNG ALVEOLUS PROTEINOSIS; LUNG DYSPLASIA; LUNG HEMOSIDEROSIS; LUNG SARCOIDOSIS; NEPHROLITHIASIS; NEUROTOXICITY; NONHUMAN; PHYSIOTHERAPY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; RETROLENTAL FIBROPLASIA; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; SIDE EFFECT; SYSTEMIC THERAPY; TREATMENT OUTCOME; WHEEZING;

AGE FACTORS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; LUNG DISEASES; RESPIRATORY SYSTEM AGENTS;

EID: 70349139544     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00166508     Document Type: Review

References (284)

1. The GRADE working group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490-1497.
2. Fujiwara T, Maeta H, Chida S, et al. Artificial surfactant therapy in hyaline-membrane disease. Lancet 1980; 1: 55-59. (Pubitemid 10199398)
3. Soll RF. Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 1998; 3: CD001149.
4. Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 1998; 2: CD001079.
5. Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 1997; 4: CD000511.
6. Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2001; 2: CD000144.
7. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2001; 2: CD000510.
8. Yost CC, Soll RF. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 1999; 4: CD001456.
9. Soll RF. Multiple versus single dose natural surfactant extract for severe neonatal respiratory distress syndrome. Cochrane Database Syst Rev 1999; 2: CD000141.
10. Moya F, Gadzinowski J, Bancalari E, et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome in very preterm infants. Pediatrics 2005; 115: 1018-1029.
11. Sinha S, Lacaze-Masmonteil T, Valls I, et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa in very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005; 115: 1030-1038.
12. Pfister RH, Soll RF, Wiswell T. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev 2007; 4: CD006069. (Pubitemid 351805340)
13. Long W, Corbet A, Cotton R, et al. American Exosurf Neonatal Study Group 1, and the Canadian Exosurf Neonatal Study Group. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. N Engl J Med 1991; 325: 1696-1703.
14. Darlow BA, Graham BJ. Vitamin A supplementation to prevent mortality and short and long term morbidity in very low birthweight infants. Cochrane Database Syst Rev 2008; 1: CD000501.
15. Bental RY, Cooper PA, Sandler D, et al. The effects of vitamin A therapy on the incidence of chronic lung disease in premature infants. Pediatr Res 1990; 25: 296A.
16. Papagaroufalis C, Cairis M, Pantazatou E, et al. A trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. Pediatr Res 1988; 23: 518A.
17. Pearson E, Bose C, Snidow T, et al. Trial of vitamin A supplementation in very low birthweight infants at risk for bronchopulmonary dysplasia. J Pediatr 1992; 121: 420-427.
18. Ravishankar C, Nafday S, Green RS, et al. A trial of vitamin A therapy to facilitate ductal closure in premature infants. J Pediatr 2003; 143: 644-648. (Pubitemid 37452794)
19. Shenai JP, Kennedy KA, Chytil F, et al. Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. J Pediatr 1987; 111: 269-277. (Pubitemid 17127140)
20. Ambalavanan N, Tyson JE, Kennedy KA, et al. National Institute of Child Health and Human Development Neonatal Research Network. Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. Pediatrics 2005; 115: e249-e254.
21. Werkman SH, Peeples JM, Cooke RJ, et al. Effect of vitamin A supplementation of intravenous lipids on early vitamin A intake and status of premature infants. Am J Clin Nutrition 1994; 59: 586-592.
22. Wardle SP, Hughes A, Chen S, et al. Randomised controlled trials of oral vitamin A supplementation in preterm infants to prevent chronic lung disease. Arch Dis Child Fetal Neonatal Ed 2001; 84: F9-F13. (Pubitemid 32060163)
23. Ambalavanan N, Wu T-J, Tyson JE, et al. A comparison of three vitamin A dosing regimens in extremely low birthweight infants. J Pediatr 2003; 142: 656-661. (Pubitemid 36737169)
24. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; 1: CD001146.
25. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; 1: CD001144.
26. Doyle LW, Halliday HL, Ehrenkranz RA, et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 2005; 115: 655-661.
27. Doyle LW, Davis PG, Morley CJ, et al. Low dose dexamethasone facilitates extubation among chronically ventilator dependent infants: a multicentre, international, randomized controlled trial. Pediatrics 2006; 117: 75-83.
28. Doyle LW, Davis PG, Morley CJ, et al. Outcome at two years of age of infants from the DART study: a multicentre, international, randomized controlled trial of low dose dexamethasone. Pediatrics 2007; 119: 716-721. (Pubitemid 46556670)
29. Watterberg KL, Gerdes JS, Gifford KL, et al. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 1999; 104: 1258-1263.
30. Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004; 114: 1649-1657.
31. Bonsante F, Latorre G, Iacobelli S, et al. Early low dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. Neonatology 2007; 91: 217-221. (Pubitemid 46934203)
32. Shah SS, Ohlsson A, Halliday H, et al. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birthweight preterm infants. Cochrane Database Syst Rev 2007; 4: CD001969. (Pubitemid 351805213)
33. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2006; 4: CD000399.
34. Hogman M, Frostell C, Arnberg H, et al. Bleeding time prolongation and nitric oxide inhalation. Lancet 1993; 341: 1664-1665. (Pubitemid 23175283)
35. Cheung PY, Salas E, Etches PC, et al. Inhaled nitric oxide and inhibition of platelet aggregation in critically ill neonates. Lancet 1998; 351: 1181-1182. (Pubitemid 28171832)
36. Van Meurs KP, Rhine WD, Asselin JM, et al. Preemie NO Collaborative Group. Response of premature infants with severe respiratory failure to inhaled nitric oxide. Pediatr Pulmonol 1997; 24: 319-323.
37. Barrington KJ, Finer NN. Inhaled nitric oxide for preterm infants. A systematic review. Pediatrics 2007; 120: 1088-1099.
38. Ballard RA, Truog WE, Cnaan A, et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006; 355: 343-353. (Pubitemid 44127537)
39. Mestan KKL, Marks JD, Hecox K, et al. Neurodevelopmental outcome of premature infants treated with inhaled nitric oxide. N Engl J Med 2005; 352: 23-32. (Pubitemid 41007804)
40. Tanaka Y, Hayashi T, Kitajima H, et al. Inhaled nitric oxide therapy decreases the risk of cerebral palsy in preterm infants with persistent pulmonary hypertension of the newborn. Pediatrics 2007; 119: 1159-1164. (Pubitemid 46871272)
41. Kinsella JP, Parker TA, Galan H, et al. Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease. Pediatr Res 1997; 41: 457-463. (Pubitemid 27147859)
42. Hallman M. Molecular interactions between nitric oxide and lung surfactant. Biol Neonate 1997; 71: 44-48. (Pubitemid 27254240)
43. Schreiber MD, Gin-Mestran K, Marks JD, et al. Inhaled nitric oxide in premature infants with respiratory distress syndrome. N Engl J Med 2003; 349: 2099-2107. (Pubitemid 37464534)
44. Kinsella JP, Cutter GR, Walsh WF, et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 2006; 355: 354-364. (Pubitemid 44127538)
45. Howlett A, Ohlsson A. Inositol for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2003; 4: CD000366.
46. Ng GY, da Silva O, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev 2001; 2: CD003214.
47. Ng GY, Ohlsson A. Cromolyn sodium for the prevention of chronic lung disease in preterm infants. Cochrane Database Syst Rev 2001; 1: CD003059.
48. Wang EEL, Ohlsson A, Kellner JD. Association of Ureaplasma urealyticum colonization with chronic lung disease of prematurity: results of a meta-analysis. J Pediatr 1995; 127: 640-644.
49. Mabanta CG, Pryhuber GS, Weinberg GA, et al. Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. Cochrane Database Syst Rev 2003; 4: CD003744.
50. Baier RJ, Loggins J, Kruger TE. Failure of erythromycin to eliminate airway colonization with Ureaplasma urealyticum in very low birth weight infants. BMC Pediatr 2003; 3: 10. (Pubitemid 38729216)
51. Ballard HO, Bernard P, Qualls J, et al. Azithromycin protects against hyperoxic lung injury in neonatal rats. J Invest Med 2007; 55: 299-305. (Pubitemid 350205424)
52. Aghai ZH, Kode A, Saslow JG, et al. Azithromycin suppresses activation of nuclear factor-κB and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res 2007; 62: 483-488. (Pubitemid 47476210)
53. Ballard HO, Anstead MI, Shook LA. Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study. Respir Res 2007; 8: 41.
54. Padmanabhan R, Gudapaty R, Liener I, et al. Protection against pulmonary oxygen toxicity in rats by the intratracheal administration of liposome-encapsulated superoxide dismutase or catalase. Am J Respir Dis 1985; 132: 164-167. (Pubitemid 15026206)
55. Davis JM, Rosenfeld W, Richter SE, et al. Safety and pharmacokinetics of multiple doses of recombinant human CuZn superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics 1997; 100: 24-30. (Pubitemid 27291004)
56. Davis JM, Parad RB, Michele T, et al. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics 2003; 111: 469-476. (Pubitemid 36330700)
57. Ahola T, Lapatto R, Raivio KO, et al. N-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial. J Pediatr 2003; 143: 713-719. (Pubitemid 37510637)
58. Sandberg K, Fellman V, Stigson L, et al. N-acetylcysteine administration during the first week of life does not improve lung function in extremely low birth weight infants. Biol Neonate 2004; 86: 275-279. (Pubitemid 39482597)
59. Russell GA, Cooke RW. Randomised controlled trial of allopurinol prophylaxis in very preterm infants. Arch Dis Child Fetal Neonatal Ed 1995; 73: F27-F31.
60. Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36: 1-9. (Pubitemid 38130283)
61. Gitto E, Reiter RJ, Sabatino G, et al. Correlation among cytokines, bronchopulmonary dysplasia and modality of ventilation in preterm newborns: improvement with melatonin treatment. J Pineal Res 2005; 39: 287-293. (Pubitemid 41337810)
62. Brion LP, Bell EF, Raghuveer TS. Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2003; 4: CD003665.
63. Hazinski TA, France M, Kennedy KA, et al. Cimetidine reduces hyperoxic lung injury in lambs. J Appl Physiol 1989; 67: 2586-2592. (Pubitemid 20032265)
64. Cotton RB, Hazinski TA, Morrow JD, et al. Cimetidine does not prevent lung injury in newborn premature infants. Pediatr Res 2006; 59: 795-800.
65. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006; 354: 2112-2121.
66. Schmidt B, Roberts RS, Davis P, et al. Long term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007; 357: 1893-1902. (Pubitemid 350074685)
67. Little S, Dean T, Bevin S, et al. Role of elevated plasma soluble ICAM-1 and bronchial lavage fluid IL-8 levels as markers of chronic lung disease in premature infants. Thorax 1995; 50: 1073-1079.
68. ter Horst SA, Wagenaar GT, de Boer E, et al. Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury. J Appl Physiol 2004; 97: 2014-2019.
69. Lauterbach R, Szymura-Oleksiak J. Nebulized pentoxifylline in successful treatment of five premature neonates with bronchopulmonary dysplasia. Eur J Pediatr 1999; 158: 607. (Pubitemid 29288036)
70. Lauterbach R, Szymura-Oleksiak J, Pawlik D, et al. Nebulised pentoxifylline for prevention of bronchopulmonary dysplasia in very low birthweight infants: a pilot clinical study. J Matern Fetal Neonatal Med 2006; 19: 433-448. (Pubitemid 44272918)
71. Massaro GD, Mortola JP, Massaro D. Estrogen modulates the dimensions of the lung's gas exchange surface area and alveoli in female rats. Am J Physiol 1996; 270: L110-L114. (Pubitemid 126756043)
72. Trotter A, Ebsen M, Kiossis E, et al. Prenatal estrogen and progesterone deprivation impairs alveolar formation and fluid clearance in newborn piglets. Pediatr Res 2006; 60: 60-64. (Pubitemid 44297614)
73. Trotter A, Maier L, Kron M, et al. Effect of oestradiol and progesterone replacement on bronchopulmonary dysplasia in extremely preterm infants. Arch Dis Child Fetal Neonatal Ed 2007; 92: F94-F98. (Pubitemid 46423819)
74. Moya MP, Gow AJ, McMahon TJ, et al. S-nitrosothiol repletion by an inhaled gas regulates pulmonary function. Proc Nat Acad Sci USA 2001; 98: 5792-5797.
75. Auten RL, Mason SN, Whorton MH, et al. Inhaled ethyl nitrate prevents hyperoxia impaired postnatal alveolar development in newborn rats. Am J Respir Crit Care Med 2007; 176: 291-299.
76. Merrill JD, Ballard RA, Cnaan A, et al. Dysfunction of pulmonary surfactant in chronically ventilated premature infants. Pediatr Res 2004; 56: 918-926. (Pubitemid 39552774)
77. Cogo PE, Zimmermann LJ, Pesavento R, et al. Surfactant kinetics in preterm infants on mechanical ventilation who did and did not develop bronchopulmonary dysplasia. Crit Care Med 2003; 31: 1532-1538. (Pubitemid 36583870)
78. Pandit PB, Dunn MS, Kelly EN, et al. Surfactant replacement in neonates with early chronic lung disease. Pediatrics 1995; 95: 851-854.
79. Katz LA, Klein JM. Repeat surfactant therapy for postsurfactant slump. J Perinatol 2006; 26: 414-422.
80. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; 1: CD001145.
81. Brion LP, Primhak RA. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2000; 4: CD001453.
82. Brion LP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterminfants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2002; 1: CD001817.
83. Brion LP, Primhak RA, Yong W. Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2006; 2: CD001694.
84. Najak ZD, Harris EM, Lazzara A, et al. Pulmonary effects of furosemide in preterm infants with lung disease. J Pediatr 1983; 102: 758-763.
85. McCann EM, Lewis K, Deming DD, et al. Controlled trial of furosemide therapy in infants with chronic lung disease. J Pediatr 1985; 106: 957-962. (Pubitemid 15006650)
86. Singhal N, McMilan DD, Rademaker AW. Furosemide improves lung compliance in infants with bronchopulmonary dysplasia. Pediatr Res 1983; 17: 336A.
87. Rush MG, Engelhardt B, Parker RA, et al. Double-blind placebo-controlled trial of alternate day furosemide therapy in infants with chronic bronchopulmonary dysplasia. J Pediatr 1990; 117: 112-118. (Pubitemid 20217508)
88. Reiter PD, Makhlouf R, Stiles AD. Comparison of 6-hour infusion versus bolus furosemide in premature infants. Pharmacotherapy 1998; 18: 63-68. (Pubitemid 28059005)
89. Albersheim S, Solimano A, Sharma AK, et al. Randomized double-blind, controlled trial of long term diuretic therapy for bronchopulmonary dysplasia. J Pediatr 1989; 115: 615-620. (Pubitemid 19248846)
90. Engelhart B, Blalock WA, DonLevy S, et al. Effect of spironolactone- hydrochlorothiazide on lung function in infants with chronic bronchopulmonary dysplasia. J Pediatr 1989; 114: 619-624. (Pubitemid 19098297)
91. Kao LC, Durand DJ, McCrea RC, et al. Randomised trial of long term diuretic therapy for infants with oxygen dependent bronchopulmonary dysplasia. J Pediatr 1994; 124: 772-781.
92. Kao LC, Warburton D, Cheng MH, et al. Effect of oral diuretics on pulmonary mechanics in infants with chronic bronchopulmonary dysplasia. Results of a double-blind crossover sequential trial. Pediatrics 1984; 74: 37-44.
93. Hoffman DJ, Gerdes JS, Abbasi S. Pulmonary function and electrolyte balance following spironalactone treatment in preterm infants with chronic lung disease. A double-blind, placebocontrolled, randomized trial. J Perinatol 2000; 20: 41-45.
94. Segar JL, Chemtob S, Bell EF. Changes in body water compartments with diuretic therapy in infants with chronic lung disease. Early Hum Dev 1997; 48: 99-107. (Pubitemid 27153932)
95. Cabal LA, Larrazabal C, Ramanathan R, et al. Effects of metaproterenol on pulmonary mechanics, oxygenation and ventilation in infants with chronic lung disease. J Pediatr 1987; 110: 116-119. (Pubitemid 17211896)
96. Denjean A, Guimaraes H, Migdal M, et al. Dose-related bronchodilator response to aerosolized salbutamol (albuterol) in ventilator-dependent premature infants. J Pediatr 1992; 120: 974-979.
97. Wilkie RA, Bryan MH. Effect of bronchodilators on airway resistance in ventilator-dependent neonates with chronic lung disease. J Pediatr 1987; 111: 278-282.
98. Kao LC, Durand DJ, Nickerson BG. Effects of inhaled metaproterenol and atropine on the pulmonary mechanics of infants with bronchopulmonary dysplasia. Pediatr Pulmonol 1989; 6: 74-80.
99. Abman S, Sondheimer H. Pulmonary circulation and cardiovascular sequelae of BPD. In: Weir EK, Archer SL, Reeves JT, eds. Diagnosis and Treatment of Pulmonary Hypertension. New York, Futura, 1992; pp. 155-180.
100. Goodman G, Perkin RM, Anas NG, et al. Pulmonary hypertension in infants with bronchopulmonary dysplasia. J Pediatr 1988; 112: 67-72. (Pubitemid 18054274)
101. Walther FJ, Bendes FJ, Leighton JO. Persistent pulmonary hypertension in premature neonates with severe respiratory distress syndrome. Pediatrics 1992; 90: 899-904.
102. Stenmark KR, Abman SH. Lung vascular development: Implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol 2005; 67: 623-661. (Pubitemid 40404504)
103. Kasian GF, Ninan A, Duncan WJ, et al. Treatment of pulmonary hypertension with diltiazem in a child with bronchopulmonary dysplasia. Can J Cardiol 1988; 4: 181-184. (Pubitemid 18148007)
104. Rugulotto S, Errico G, Beghini R, et al. Weaning of epoprostenol in a small infant receiving concomitant bosentan for severe pulmonary arterial hypertension secondary to bronchopulmonary dysplasia. Minerva Pediatr 2006; 58: 491-494. (Pubitemid 44690319)
105. Bush A, Busst CM, Knight WB. Changes in pulmonary circulation in severe bronchopulmonary dysplasia. Arch Dis Child 1990; 65: 739-745. (Pubitemid 20220432)
106. Hon KL, Cheung KL, Siu KL, et al. Oral sildenafil for treatment of severe pulmonary hypertension in an infant. Biol Neonate 2005; 88: 109-112. (Pubitemid 41159823)
107. Jonson CE, Beekman RH, Kostyshak DA. Pharmacokinetics and pharmacodynamics of nifedipine in children with bronchopulmonary dysplasia and pulmonary hypertension. Pediatr Res 1991; 29: 500-503.
108. Brownlee JR, Beekman RH, Rosenthal A. Acute hemodynamic effects of nifedipine in infants with bronchopulmonary dysplasia and pulmonary hypertension. Pediatr Res 1988; 24: 186-190. (Pubitemid 18186894)
109. Banks BA, Seri I, Ischiropoulos H, et al. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. Pediatrics 1999; 103: 610-618. (Pubitemid 29274509)
110. Tsao K, Hawgood S, Vu L, et al. Resolution of hydrops fetalis in congenital cystic adenomatoid malformation after prenatal steroid therapy. J Pediatr Surg 2003; 38: 508-510. (Pubitemid 36278721)
111. Peranteau WH, Wilson RD, Liechty KW, et al. Effect of maternal betamethasone administration on prenatal congenital cystic adenomatoid malformation growth and fetal survival. Fetal Diagn Ther 2007; 22: 365-371.
112. Leung WC, Ngai C, Lam TP, et al. Unexpected intrauterine death following resolution of hydrops fetalis after betamethasone treatment in a fetus with a large cystic adenomatoid malformation of the lung. Ultrasound Obstet Gynecol 2005; 25: 610-612. (Pubitemid 40835468)
113. Smyth RL, Openshaw PJ. Bronchiolitis. Lancet 2006; 368: 312-322.
114. McDonald NE, Hall CB, Suffin SC, et al. Respiratory syncytial virus infection in infants with congenital heart disease. N Engl J Med 1982; 307: 397-400. (Pubitemid 12089293)
115. Bont L, Kimpen JL. Immunological mechanisms of severe respiratory syncytial virus bronchiolitis. Intensive Care Med 2002; 28: 616-621. (Pubitemid 34594594)
116. Bloemers BL, van Furth AM, Weijerman ME, et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis - a prospective birth-cohort study. Pediatrics 2007; 120: e1076-e1081.
117. Simoes EAF. Respiratory syncytial virus infection. Lancet 1999; 354: 847-852.
118. Gadomski AM, Bhasale AL. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev 2006; 3: CD001266.
119. Wainwright C, Altamirano L, Cheney M, et al. A multicenter, randomized, double-blind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis. N Engl J Med 2003; 349: 27-35. (Pubitemid 36765100)
120. Hartling L, Wiebe N, Russell K, et al. Epinephrine for bronchiolitis. Cochrane Database Syst Rev 2004; 1: CD003123.
121. American Academy of Pediatrics. Diagnosis and management of bronchiolitis. Pediatrics 2006; 118: 1774-1793.
122. Kimpen JL. Management of respiratory syncytial virus infection. Curr Opin Infect Dis 2001; 14: 323-328. (Pubitemid 32493545)
123. Barben J, Kuehni CE, Trachsel D, et al. Management of acute bronchiolitis: can evidence based guidelines alter clinical practice? Thorax 2008; 63: 1103-1109.
124. Richter H, Seddon P. Early nebulized budesonide in the treatment of bronchiolitis and the prevention of postbronchiolitic wheezing. J Pediatr 1998; 132: 849-853. (Pubitemid 28232939)
125. Cade A, Brownlee KG, Conway SP, et al. Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis. Arch Dis Child 2000; 82: 126-130. (Pubitemid 30305706)
126. Bentur L, Shoseyov D, Feigenbaum D, et al. Dexamethasone inhalations in RSV bronchiolitis: a double-blind, placebo-controlled study. Acta Paediatr 2005; 94: 866-871. (Pubitemid 41044769)
127. Bisgaard H, Hermansen MN, Loland L, et al. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2006; 354: 1998-2005.
128. Blom D, Ermers M, Bont L, et al. Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing. Cochrane Database Syst Rev 2007; 1: CD004881. (Pubitemid 351820477)
129. Patel H, Platt R, Lozano JM, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev 2004; 3: CD004878.
130. Teeratakulpisarn J, Limwattananon C, Tanupattarachai S, et al. Efficacy of dexamethasone injection for acute bronchiolitis in hospitalized children: a randomized, double-blind, placebo-controlled trial. Pediatr Pulmonol 2007; 42: 433-439. (Pubitemid 46700941)
131. Corneli HM, Zorc JJ, Majahan P, et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med 2007; 357: 331-339. (Pubitemid 47124133)
132. van Woensel JB, van Aalderen WM, de Weerd W, et al. Dexamethasone for treatment of patients mechanically ventilated for lower respiratory tract infection caused by respiratory syncytial virus. Thorax 2003; 58: 383-387.
133. Da Dalt L, Callegaro S, Carraro S, et al. Nasal lavage leukotrienes in infants with RSV bronchiolitis. Pediatr Allergy Immunol 2007; 18: 100-104. (Pubitemid 46333726)
134. Amirav I, Luder AS, Kruger N, et al. A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis. Pediatrics 2008; 122: e1249-e1255.
135. Bisgaard H. Montelukast in RSV-bronchiolitis. Am J Respir Crit Care Med 2004; 169: 542-543.
136. Bisgaard H, Flores-Nunez A, Goh A, et al. Study of montelukast for the treatment of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med 2008; 178: 854-860.
137. Fuller H, Del Mar C. Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst Rev 2006; 4: CD004883. (Pubitemid 46841222)
138. The Impact Study Group. Palimivumab reduces hospitalisation from respiratory syncytial virus infection in high risk infants. Pediatrics 1998; 102: 531-537.
139. Bloomfield P, Dalton D, Karleka A, et al. Bacteraemia and antibiotic use in respiratory syncytial virus infections. Arch Dis Child 2004; 89: 363-367. (Pubitemid 38523628)
140. Field CM, Connolly JH, Murtagh G, et al. Antibiotic treatment of epidemic bronchiolitis- a double-blind trial. Br Med J 1966; 1: 83-85.
141. Tahan F, Ozcan A, Koc N. Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial. Eur Respir J 2007; 29: 91-97. (Pubitemid 46092003)
142. Kneyber MC, van Woensel JB, Uijtendaal E, et al. Azithromycin does not improve disease course in hospitalized infants with respiratory syncytial virus (RSV) lower respiratory tract disease: a randomized equivalence trial. Pediatr Pulmonol 2008; 43: 142-149. (Pubitemid 351273041)
143. Ventre K, Randolph A. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2004; 4: CD000181.
144. King VJ, Viswanathan M, Bordley WC, et al. Pharmacologic treatment of bronchiolitis in infants and children: a systematic review. Arch Pediatr Adolesc Med 2004; 158: 127-137. (Pubitemid 38173966)
145. Perrotta C, Ortiz Z, Roque M. Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old. Cochrane Database Syst Rev 2007; 1: CD004873. (Pubitemid 351820410)
146. Sarrell EM, Tal G, Witzling M, et al. Nebulized 3% hypertonic saline solution treatment in ambulatory children with viral bronchiolitis decreases symptoms. Chest 2002; 122: 2015-2020. (Pubitemid 36051138)
147. Mandelberg A, Tal G, Witzling M, et al. Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis. Chest 2003; 123: 481-487. (Pubitemid 36269434)
148. Kuzik BA, Al-Qadhi SA, Kent S, et al. Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants. J Pediatr 2007; 151: 266-270. (Pubitemid 47284136)
149. Fitzgerald DA, Kilham HA. Bronchiolitis: assessment and evidence-based management. Med J Aust 2004; 180: 399-404.
150. Grigg J, Silverman M. Wheezing disorders in young children: one disease or several phenotypes? In: Frey U, Gerritsen J, eds. Respiratory Diseases in Infants and Children. Eur Respir Mon 2006; 37: 153-169.
151. Carlsen KH. What distinguishes the asthmatic amongst the infant wheezers? Pediatr Allergy Immunol 1997; 8: s40-s45.
152. Spycher BD, Silverman M, Brooke AM, et al. Distinguishing phenotypes of childhood wheeze and cough using latent class analysis. Eur Respir J 2008; 31: 974-981.
153. Corneli HM, Zorc JJ, Majahan P, et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med 2007; 357: 331-339. (Pubitemid 47124133)
154. Stafler P. Dexamethasone for bronchiolitis. N Engl J Med 2007; 357: 1659-1660.
155. Parrott RH, Kim HW, Arrobio JO, et al. Epidemiology of respiratory syncytial virus infection in Washington, DC. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol 1973; 98: 289-300.
156. McIntosh K, Ellis EF, Hoffman LS, et al. Association of viral and bacterial respiratory infection with exacerbations of wheezing in young asthmatic children. J Pediatr 1973; 82: 578-590.
157. Carlsen KH, Orstavik I, Halvorsen K. Viral infections of the respiratory tract in hospitalized children. A study from Oslo during a 90 months' period. Acta Paediatr Scand 1983; 72: 53-58.
158. Carlsen KH, Orstavik I. Bronchopulmonary obstruction in children with respiratory virus infections. Eur J Respir Dis 1984; 65: 92-98. (Pubitemid 14188703)
159. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001; 7: 719-724. (Pubitemid 32588029)
160. Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995; 310: 1225-1229.
161. Greve JM, Davis G, Meyer AM, et al. The major human rhinovirus receptor is ICAM-1. Cell 1989; 56: 839-847. (Pubitemid 19082519)
162. Lemanske RF Jr, Jackson DJ, Gangnon RE, et al. Rhinovirus illnesses during infancy predict subsequent childhood wheezing. J Allergy Clin Immunol 2005; 116: 571-577.
163. Brand PL, Baraldi E, Bisgaard H, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J 2008; 32: 1096-1110.
164. Chavasse R, Seddon P, Bara A, et al. Short acting β-agonists for recurrent wheeze in children under 2 years of age. Cochrane Database Syst Rev 2002; 3: CD002873.
165. 2-agonists for the treatment of wheezy bronchitis? Ann Allergy 1986; 57: 439-441.
166. Prendiville A, Green S, Silverman M. Airway responsiveness in wheezy infants: evidence for functional β-adrenergic receptors. Thorax 1987; 42: 100-104. (Pubitemid 17020309)
167. Kraemer R, Frey U, Sommer CW, et al. Short-term effect of albuterol, delivered via a new auxiliary device, in wheezy infants. Am Rev Respir Dis 1991; 144: 347-351.
168. Bentur L, Canny GJ, Shields MD, et al. Controlled trial of nebulized albuterol in children younger than 2 years of age with acute asthma. Pediatrics 1992; 89: 133-137.
169. Clarke JR, Aston H, Silverman M. Delivery of salbutamol by metered dose inhaler and valved spacer to wheezy infants: effect on bronchial responsiveness. Arch Dis Child 1993; 69: 125-129. (Pubitemid 23233005)
170. Fox GF, Marsh MJ, Milner AD. Treatment of recurrent acute wheezing episodes in infancy with oral salbutamol and prednisolone. Eur J Pediatr 1996; 155: 512-516.
171. Kraemer R, Graf Bigler U, Casaulta Aebischer C, et al. Clinical and physiological improvement after inhalation of low-dose beclomethasone dipropionate and salbutamol in wheezy infants. Respiration 1997; 64: 342-349. (Pubitemid 27365661)
172. Chavasse RJ, Bastian-Lee Y, Richter H, et al. Inhaled salbutamol for wheezy infants: a randomised controlled trial. Arch Dis Child 2000; 82: 370-375. (Pubitemid 30307764)
173. Skoner DP, Greos LS, Kim KT, et al. Evaluation of the safety and efficacy of levalbuterol in 2-5-year-old patients with asthma. Pediatr Pulmonol 2005; 40: 477-486. (Pubitemid 41720703)
174. Nielsen KG, Bisgaard H. Bronchodilation and bronchoprotection in asthmatic preschool children from formoterol administered by mechanically actuated dry-powder inhaler and spacer. Am J Respir Crit Care Med 2001; 164: 256-259. (Pubitemid 34001291)
175. Browne GJ, Penna AS, Phung X, et al. Randomised trial of intravenous salbutamol in early management of acute severe asthma in children. Lancet 1997; 349: 301-305. (Pubitemid 27056820)
176. Panickar JR, Grigg J. Controversies in the management of preschool viral wheeze. Paediatr Respir Rev 2006; 7: 293-298. (Pubitemid 44689275)
177. Wilson NM, Silverman M. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home. Arch Dis Child 1990; 65: 407-410. (Pubitemid 20145468)
178. Connett G, Lenney W. Prevention of viral induced asthma attacks using inhaled budesonide. Arch Dis Child 1993; 68: 85-87. (Pubitemid 23039303)
179. Svedmyr J, Nyberg E, Asbrink-Nilsson E, et al. Intermittent treatment with inhaled steroids for deterioration of asthma due to upper respiratory tract infections. Acta Paediatr 1995; 84: 884-888.
180. Ducharme FM, Lemire C, Noya FJ, et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med 2009; 360: 339-353.
181. Oommen A, Lambert PC, Grigg J. Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial. Lancet 2003; 362: 1433-1438. (Pubitemid 37352878)
182. Csonka P, Kaila M, Laippala P, et al. Oral prednisolone in the acute management of children age 6 to 35 months with viral respiratory infection-induced lower airway disease: a randomized, placebo-controlled trial. J Pediatr 2003; 143: 725-730. (Pubitemid 37510639)
183. Panickar J, Lakhanpaul M, Lambert PC, et al. Oral prednisolone for preschool children with acute virus-induced wheezing. N Engl J Med 2009; 360: 329-338.
184. Bacharier LB, Phillips BR, Zeiger RS, et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol 2008; 122: 1127-1135.
185. Wilson N, Sloper K, Silverman M. Effect of continuous treatment with topical corticosteroid on episodic viral wheeze in preschool children. Arch Dis Child 1995; 72: 317-320.
186. Kaditis AG, Winnie G, Syrogiannopoulos GA. Anti-inflammatory pharmacotherapy for wheezing in preschool children. Pediatr Pulmonol 2007; 42: 407-420. (Pubitemid 46700939)
187. 2- agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev 2005; 4: CD005535.
188. Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171: 315-322. (Pubitemid 40223397)
189. Robertson CF, Price D, Henry R, et al. Short-course montelukast for intermittent asthma in children: a randomised controlled trial. Am J Respir Crit Care Med 2007; 175: 323-329. (Pubitemid 46271555)
190. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115: 233-242.
191. de Benedictis FM, del Giudice MM, Forenza N, et al. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. Eur Respir J 2006; 28: 291-295. (Pubitemid 44914226)
192. Bisgaard H, Flores-Nunez A, Goh A, et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med 2008; 178: 854-860.
193. Davis GM, Cooper DM, Mitchell I. The measurement of thoracoabdominal asynchrony in infants with severe laryngotracheobronchitis. Chest 1993; 103: 1842-1848. (Pubitemid 23174324)
194. Bjornson CL, Johnson DW. Croup-treatment update. Pediatr Emerg Care 2005; 21: 863-873.
195. Cherry JD. Croup. N Engl J Med 2008; 358: 384-391.
196. Bjornson CL, Johnson DW. Croup. Lancet 2008; 371: 329-339.
197. Moore M, Little P. Humidified air inhalation for treating croup. Cochrane Database Syst Rev 2006; 3: CD002870.
198. Scolnik D, Coates AL, Stephens D, et al. Controlled delivery of high versus low humidity versus mist therapy for croup in emergency departments: a randomized controlled trial. JAMA 2006; 295: 1274-1280.
199. Kairys SW, Olmstead EM, O'Connor GT. Steroid treatment of laryngotracheitis: a meta-analysis of the evidence from randomized trials. Pediatrics 1989; 83: 683-693. (Pubitemid 19120509)
200. Ausejo M, Saenz A, Pham B, et al. The effectiveness of glucocorticoids in treating croup: meta-analysis. BMJ 1999; 319: 595-600. (Pubitemid 29414552)
201. Russell K, Wiebe N, Saenz A, et al. Glucocorticoids for croup. Cochrane Database Syst Rev 2003; 4: CD001955.
202. Tibballs J, Shann FA, Landau LI. Placebo-controlled trial of prednisolone in children intubated for croup. Lancet 1992; 340: 745-748.
203. Geelhoed GC, Macdonald WB. Oral and inhaled steroids in croup: a randomized, placebo-controlled trial. Pediatr Pulmonol 1995; 20: 355-361.
204. Johnson DW, Jacobson S, Edney PC, et al. A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup.N Engl J Med 1998; 339: 498-503.
205. Klassen TP, Craig WR, Moher D, et al. Nebulized budesonide and oral dexamethasone for treatment of croup: a randomized controlled trial. JAMA 1998; 279: 1629-1632. (Pubitemid 28248588)
206. Cetinkaya F, Tü fekçi BS, Kutluk G. A comparison of nebulized budesonide, and intramuscular, and oral dexamethasone for treatment of croup. Int J Pediatr Otorhinolaryngol 2004; 68: 453-456.
207. Geelhoed GC. Budesonide offers no advantage when added to oral dexamethasone in the treatment of croup. Pediatr Emerg Care 2005; 21: 359-362.
208. Rittichier KK, Ledwith CA. Outpatient treatment of moderate croup with dexamethasone: intramuscular versus oral dosing. Pediatrics 2000; 106: 1344-1348.
209. Donaldson D, Poleski D, Knipple E, et al. Intramuscular versus oral dexamethasone for the treatment of moderate-to-severe croup: a randomized, double-blind trial. Acad Emerg Med 2003; 10: 16-21. (Pubitemid 36077425)
210. Amir L, Hubermann H, Halevi A, et al. Oral betamethasone versus intramuscular dexamethasone for the treatment of mild to moderate viral croup: a prospective, randomized trial. Pediatr Emerg Care 2006; 22: 541-544. (Pubitemid 44257955)
211. Sparrow A, Geelhoed G. Prednisolone versus dexamethasone in croup: a randomised equivalence trial. Arch Dis Child 2006; 91: 580-583. (Pubitemid 44023355)
212. Fifoot AA, Ting JY. Comparison between single-dose oral prednisolone and oral dexamethasone in the treatment of croup: a randomized, double-blinded clinical trial. Emerg Med Australas 2007; 19: 51-58.
213. -1. Pediatr Pulmonol 1995; 20: 362-368.
214. -1 for the treatment of moderate to severe croup. Int J Pediatr Otorhinolaryngol 2007; 71: 473-477.
215. Mendes ES, Pereira A, Danta I, et al. Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids. Eur Respir J 2003; 21: 989-993. (Pubitemid 36675615)
216. Taussig LM, Castro O, Beaudry PH, et al. Treatment of laryngotracheobronchitis (croup): use of intermittent positive-pressure breathing and racemic epinephrine. Am J Dis Child 1975; 129: 790-793.
217. Westley CR, Cotton EK, Brooks JG. Nebulized racemic epinephrine by IPPB for the treatment of croup: a double-blind study. Am J Dis Child 1978; 132: 484-487.
218. Fogel JM, Berg IJ, Gerber MA, et al. Racemic epinephrine in the treatment of croup: nebulization alone versus nebulization with intermittent positive pressure breathing. J Pediatr 1982; 101: 1028-1031.
219. Lenney W, Milner AD. Treatment of acute viral croup. Arch Dis Child 1978; 53: 704-706.
220. Corkey CW, Barker GA, Edmonds JF, et al. Radiographic tracheal diameter measurements in acute infectious croup: an objective scoring system. Crit Care Med 1981; 9: 587-590.
221. Fanconi S, Burger R, Maurer H, et al. Transcutaneous carbon dioxide pressure for monitoring patients with severe croup. J Pediatr 1990; 117: 701-705. (Pubitemid 20382599)
222. Sivan Y, Deakers TW, Newth CJ. Thoracoabdominal asynchrony in acute upper airway obstruction in small children. Am Rev Respir Dis 1990; 142: 540-544. (Pubitemid 20292712)
223. Steele DW, Santucci KA, Wright RO, et al. Pulsus paradoxus: an objective measure of severity in croup. Am J Respir Crit Care Med 1998; 157: 331-334.
224. Kristjánsson S, Berg-Kelly K, Winsö E. Inhalation of racemic adrenaline in the treatment of mild and moderately severe croup. Clinical symptom score and oxygen saturation measurements for evaluation of treatment effects. Acta Paediatr 1994; 83: 1156-1160.
225. Waisman Y, Klein BL, Boenning DA, et al. Prospective randomized double-blind study comparing L-epinephrine and racemic epinephrine aerosols in the treatment of laryngotracheitis (croup). Pediatrics 1992; 89: 302-306.
226. Fitzgerald D, Mellis C, Johnson M, et al. Nebulized budesonide is as effective as nebulized adrenaline in moderately severe croup. Pediatrics 1996; 97: 722-725. (Pubitemid 26138106)
227. Terregino CA, Nairn SJ, Chansky ME, et al. The effect of heliox on croup: a pilot study. Acad Emerg Med 1998; 5: 1130-1133.
228. Weber JE, Chudnofsky CR, Younger JG, et al. A randomized comparison of helium-oxygen mixture (Heliox) and racemic epinephrine for the treatment of moderate to severe croup. Pediatrics 2001; 107: E96.
229. Chiu CY, Wong KS, Huang YC, et al. Bronchiolitis obliterans in children: clinical presentation, therapy and long-term follow-up. J Paediatr Child Health 2008; 44: 129-133.
230. Chang AB, Masel JP, Masters B. Post-infectious bronchiolitis obliterans: clinical, radiological and pulmonary function sequelae. Pediatr Radiol 1998; 28: 23-29. (Pubitemid 28055102)
231. Moonnumakal SP, Fan LL. Bronchiolitis obliterans in children. Curr Opin Pediatr 2008; 20: 272-278.
232. Smith KJ, Fan LL. Insights into post-infectious bronchiolitis obliterans in children. Thorax 2006; 61: 462-463. (Pubitemid 43901512)
233. Castro-Rodriguez JA, Daszenies C, Garcia M, et al. Adenovirus pneumonia in infants and factors for developing bronchiolitis obliterans: a 5-year follow-up. Pediatr Pulmonol 2006; 41: 947-953. (Pubitemid 44534812)
234. Colom AJ, Teper AM, Vollmer WM, et al. Risk factors for the development of bronchiolitis obliterans in children with bronchiolitis. Thorax 2006; 61: 503-506. (Pubitemid 43901520)
235. Kim CK, Kim SW, Kim JS, et al. Bronchiolitis obliterans in the 1990s in Korea and the United States. Chest 2001; 120: 1101-1106. (Pubitemid 32960078)
236. Teper AM, Kofman CD, Maffey AF, et al. Lung function in infants with chronic pulmonary disease after severe adenoviral illness. J Pediatr 1999; 134: 730-733. (Pubitemid 30186817)
237. Cazzato S, Poletti V, Bernardi F, et al. Airway inflammation and lung function decline in childhood post-infectious bronchiolitis obliterans. Pediatr Pulmonol 2008; 43: 381-390. (Pubitemid 351544047)
238. Rossi UG, Owens CM. The radiology of chronic lung disease in children. Arch Dis Child 2005; 90: 601-607. (Pubitemid 40780721)
239. Clement A. Task force on chronic interstitial lung disease in immunocompetent children. Eur Respir J 2004; 24: 686-697. (Pubitemid 39406144)
240. Deutsch GH, Young LR, Deterding RR, et al. Diffuse lung disease in young children: application of a novel classification scheme. Am J Respir Crit Care Med 2007; 176: 1120-1128.
241. Deterding RR, Young LR, Dishop M. Diffuse lung disease in older children - report of the child network review. Am J Respir Crit Care Med 2007; 175: A148.
242. Osika E, Muller MH, Boccon-Gibod L, et al. Idiopathic pulmonary fibrosis in infants. Pediatr Pulmonol 1997; 23: 49-54.
243. Paul K, Klettke U, Moldenhauer J, et al. Increasing dose of methylprednisolone pulse therapy treats desquamative interstitial pneumonia in a child. Eur Respir J 1999; 14: 1429-1432. (Pubitemid 30019543)
244. Dinwiddie R, Sharief N, Crawford O. Idiopathic interstitial pneumonitis in children: a national survey in the United Kingdom and Ireland. Pediatr Pulmonol 2002; 34: 23-29. (Pubitemid 34686707)
245. Kim HB, Lee SY, Kim JH, et al. Familial interstitial lung disease in two young Korean sisters. J Korean Med Sci 2005; 20: 1066-1069.
246. Paiva MA, Amaral SM. Chronic interstitial lung disease in children. J Pediatr (Rio J) 2007; 83: 233-240. (Pubitemid 46887274)
247. Rigante D, Stabile A, Segni G. Chronic interstitial lung disease in a 10-year-old child. Clin Pediatr (Phila) 1998; 37: 697-699. (Pubitemid 28516644)
248. Uziel Y, Hen B, Cordoba M, et al. Lymphocytic interstitial pneumonitis preceding polyarticular juvenile rheumatoid arthritis. Clin Exp Rheumatol 1998; 16: 617-619. (Pubitemid 28439449)
249. Kobayashi I, Yamada M, Takahashi Y, et al. Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A. Rheumatology (Oxford) 2003; 42: 371-374. (Pubitemid 36305628)
250. Akikusa JD, Schneider R, Harvey EA, et al. Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Rheum 2007; 57: 837-844. (Pubitemid 46932091)
251. Tamura N, Matsudaira R, Hirashima M, et al. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med 2007; 46: 409-414. (Pubitemid 46585484)
252. Wilkinson NM, Erendzhinova E, Zeft A, et al. Infliximab as rescue therapy in three cases of paediatric Wegener's granulomatosis. Rheumatology (Oxford) 2006; 45: 1047-1048. (Pubitemid 44283068)
253. Hermon MM, Golej J, Emminger W, et al. Acute hemorrhagic respiratory failure caused by Wegener's granulomatosis successfully treated by bronchoalveolar lavage with diluted surfactant. Wien Klin Wochenschr 2003; 115: 793-796. (Pubitemid 38101159)
254. Kamali S, Cefle A, Sayarlioglu M, et al. Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases. Rheumatol Int 2005; 25: 211-214. (Pubitemid 40576788)
255. Morimoto A, Ikushima S, Kinugawa N, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer 2006; 107: 613-619. (Pubitemid 44107223)
256. Hartl D, Griese M. Interstitial lung disease in children - genetic background and associated phenotypes. Respir Res 2005; 6: 32. (Pubitemid 41358038)
257. Price A, Manson D, Cutz E, et al. Pulmonary alveolar proteinosis associated with anti-GM-CSF antibodies in a child: successful treatment with inhaled GM-CSF. Pediatr Pulmonol 2006; 41: 367-370.
258. Mahut B, de Blic J, Le Bourgeois M, et al. Partial and massive lung lavages in an infant with severe pulmonary alveolar proteinosis. Pediatr Pulmonol 1992; 13: 50-53.
259. Mahut B, Delacourt C, Scheinmann P, et al. Pulmonary alveolar proteinosis: experience with eight pediatric cases and a review. Pediatrics 1996; 97: 117-122. (Pubitemid 26012622)
260. Spock A. Long-term survival of paediatric patients with pulmonary alveolar proteinosis treated with lung lavage. Eur Respir J 2005; 25: 1127. (Pubitemid 40823791)
261. Froudarakis ME, Koutsopoulos A, Mihailidou HP. Total lung lavage by awake flexible fiberoptic bronchoscope in a 13-year-old girl with pulmonary alveolar proteinosis. Respir Med 2007; 101: 366-369. (Pubitemid 46075960)
262. Ceruti M, Rodi G, Stella GM, et al. Successful whole lung lavage in pulmonary alveolar proteinosis secondary to lysinuric protein intolerance: a case report. Orphanet J Rare Dis 2007; 2: 14.
263. Desmarquest P, Tamalet A, Fauroux B, et al. Chronic interstitial lung disease in children: response to high-dose intravenous methylprednisolone pulses. Pediatr Pulmonol 1998; 26: 332-338. (Pubitemid 29006565)
264. Kiper N, Anadol D, Ozcelik U, et al. Inhaled corticosteroids for maintenance treatment in childhood pulmonary sarcoidosis. Acta Paediatr 2001; 90: 953-956. (Pubitemid 32762848)
265. Hilton JM, Cooper DM, Henry RL, et al. Hydroxychloroquine therapy of diffuse pulmonary sarcoidosis in two Australian male children. Respirology 1997; 2: 71-74.
266. Moudgil A, Przygodzki RM, Kher KK. Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil. Pediatr Nephrol 2006; 21: 281-285. (Pubitemid 43115886)
267. Brik R, Gepstein V, Shahar E, et al. Tumor necrosis factor blockade in the management of children with orphan diseases. Clin Rheumatol 2007; 26: 1783-1785.
268. Cruz BA, Reis DD, Araujo CA, et al. Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab. Rheumatol Int 2007; 27: 1181-1183.
269. Minakuchi M, Niimi A, Matsumoto H, et al. Chronic eosinophilic pneumonia: treatment with inhaled corticosteroids. Respiration 2003; 70: 362-366. (Pubitemid 37186702)
270. Bush A, Sheppard MN, Warner JO. Chloroquine in idiopathic pulmonary haemosiderosis. Arch Dis Child 1992; 67: 625-627.
271. Rossi GA, Balzano E, Battistini E, et al. Long-term prednisone and azathioprine treatment of a patient with idiopathic pulmonary hemosiderosis. Pediatr Pulmonol 1992; 13: 176-180.
272. Zaki M, al Saleh Q, al Mutari G. Effectiveness of chloroquine therapy in idiopathic pulmonary hemosiderosis. Pediatr Pulmonol 1995; 20: 125-126.
273. Kiper N, Göçmen A, Ozçelik U, et al. Long-term clinical course of patients with idiopathic pulmonary hemosiderosis (1979-1994): prolonged survival with low-dose corticosteroid therapy. Pediatr Pulmonol 1999; 27: 180-184.
274. Colombo JL, Stolz SM. Treatment of life-threatening primary pulmonary hemosiderosis with cyclophosphamide. Chest 1992; 102: 959-960.
275. Huang SH, Lee PY, Niu CK. Treatment of pediatric idiopathic pulmonary hemosiderosis with low-dose cyclophosphamide. Ann Pharmacother 2003; 37: 1618-1621.
276. Sharief N, Crawford OF, Dinwiddie R. Fibrosing alveolitis and desquamative interstitial pneumonitis. Pediatr Pulmonol 1994; 17: 359-365.
277. Balasubramanyan N, Murphy A, O'Sullivan J, et al. Familial interstitial lung disease in children: response to chloroquine treatment in one sibling with desquamative interstitial pneumonitis. Pediatr Pulmonol 1997; 23: 55-61. (Pubitemid 27074133)
278. Stauffer Ettlin M, Pache JC, Renevey F, et al. Bird breeder's disease: a rare diagnosis in young children. Eur J Pediatr 2006; 165: 55-61. (Pubitemid 41830889)
279. du Marchie Sarvaas GJ, Merkus PJ, de Jongste JC. A family with extrinsic allergic alveolitis caused by wild city pigeons: a case report. Pediatrics 2000; 105: E62.
280. Aebischer CC, Frey U, Schöni MH. Hypersensitivity pneumonitis in a five-year-old boy: an unusual antigen source. Pediatr Pulmonol 2002; 33: 77-78. (Pubitemid 34031558)
281. Chen C, Kleinau I, Niggemann B, et al. Treatment of allergic alveolitis with methylprednisolone pulse therapy. Pediatr Allergy Immunol 2003; 14: 66-70. (Pubitemid 36603992)
282. Deutsch GH, Young LR, Deterding RR, et al. ChILD Research Cooperative. Diffuse lung disease in young children: application of a novel classification scheme. Am J Respir Crit Care Med 2007; 176: 1120-1128.
283. Deterding RR, Pye C, Fan LL, et al. Persistent tachypnea of infancy is associated with neuroendocrine cell hyperplasia. Pediatr Pulmonol 2005; 40: 157-165. (Pubitemid 41099432)
284. Canakis AM, Cutz E, Manson D, et al. Pulmonary interstitial glycogenosis: a new variant of neonatal interstitial lung disease. Am J Respir Crit Care Med 2002; 165: 1557-1565. (Pubitemid 34606674)